
![]()
Novartis Oncology Reimbursement Hotline
1-800-282-7630 *
Through the Reimbursement Hotline, Novartis Oncology is dedicated to answering your questions and providing assistance with the reimbursement process for Novartis products. By calling 1-800-282-7630, providers and patients can receive assistance in resolving reimbursement issues and concerns.
Insurance Verification
The program verifies patients' medical benefits, helps determine insurance coverage, and clarifies co-payment obligations.
Denials/appeals
The program assists providers in obtaining appropriate reimbursement.
Coding/billing questions
Program staff can assist providers with questions regarding coding and billing.
Alternative funding searches
Program staff can search for possible assistance for patients with insufficient medical benefit coverage or no drug coverage and refer to other sources of funding that could help alleviate or reduce costs.
Referrals to copay cards
Novartis Oncology has many product specific copay cards to help patients meet their copay obligations.
Referrals to patient assistance for low income uninsured patients
Letter of medical necessity
Through the hotline, copies of sample letters of medical necessity are provided.
Scheduled counselor appointments
Office practice managers can submit their questions and then schedule time to speak with a team of Novartis professionals who will seek to provide solutions to any problem.
*The Reimbursement Hotline and Novartis Pharmaceuticals Corporation do not guarantee success in obtaining reimbursement, nor do we submit appeals on behalf of providers or patients. Third-party payment for medical products and services is affected by numerous factors, not all of which can be anticipated or resolved by Reimbursement Hotline staff.
PROVIDER PORTAL

For Novartis product reimbursement support, access the Novartis Oncology Provider Portal or call or fax our Reimbursement Hotline.
OPM Newsletter
Program Finder

The Program Finder may help you get your Novartis medicines at reduced or no cost.
